vs
Side-by-side financial comparison of NovoCure Ltd (NVCR) and WSFS FINANCIAL CORP (WSFS). Click either name above to swap in a different company.
WSFS FINANCIAL CORP is the larger business by last-quarter revenue ($275.3M vs $174.1M, roughly 1.6× NovoCure Ltd). WSFS FINANCIAL CORP runs the higher net margin — 31.5% vs -40.9%, a 72.4% gap on every dollar of revenue. On growth, NovoCure Ltd posted the faster year-over-year revenue change (12.3% vs 7.5%). Over the past eight quarters, NovoCure Ltd's revenue compounded faster (7.6% CAGR vs 1.7%).
NovoCure Ltd is a global oncology company that develops and commercializes innovative Tumor Treating Fields (TTFields) therapy, a non-invasive wearable treatment using low-intensity electric fields to disrupt cancer cell division. Its approved therapies target glioblastoma, malignant mesothelioma and non-small cell lung cancer, serving patients across North America, Europe and Asia Pacific.
WSFS Financial Corporation is a financial services company. Its primary subsidiary, WSFS Bank, a federal savings bank, is the largest and longest-standing locally managed bank and wealth management franchise headquartered in Delaware and the Greater Delaware Valley. WSFS operates from 115 offices, 88 of which are banking offices, located in Pennsylvania (57), Delaware (39), New Jersey (14), Florida (2), Virginia (1), and Nevada (1) and provides comprehensive financial services including comme...
NVCR vs WSFS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $174.1M | $275.3M |
| Net Profit | $-71.1M | $86.8M |
| Gross Margin | 77.6% | — |
| Operating Margin | — | — |
| Net Margin | -40.9% | 31.5% |
| Revenue YoY | 12.3% | 7.5% |
| Net Profit YoY | -107.3% | 31.7% |
| EPS (diluted) | — | $1.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $174.1M | $275.3M | ||
| Q4 25 | $174.3M | $271.9M | ||
| Q3 25 | $167.2M | $270.5M | ||
| Q2 25 | $158.8M | $267.5M | ||
| Q1 25 | $155.0M | $256.1M | ||
| Q4 24 | $161.3M | $261.5M | ||
| Q3 24 | $155.1M | $267.7M | ||
| Q2 24 | $150.4M | $266.0M |
| Q1 26 | $-71.1M | $86.8M | ||
| Q4 25 | $-24.5M | $72.7M | ||
| Q3 25 | $-37.3M | $76.4M | ||
| Q2 25 | $-40.1M | $72.3M | ||
| Q1 25 | $-34.3M | $65.9M | ||
| Q4 24 | $-65.9M | $64.2M | ||
| Q3 24 | $-30.6M | $64.4M | ||
| Q2 24 | $-33.4M | $69.3M |
| Q1 26 | 77.6% | — | ||
| Q4 25 | 75.8% | — | ||
| Q3 25 | 73.2% | — | ||
| Q2 25 | 73.9% | — | ||
| Q1 25 | 75.1% | — | ||
| Q4 24 | 79.2% | — | ||
| Q3 24 | 77.2% | — | ||
| Q2 24 | 77.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | -23.2% | 35.8% | ||
| Q3 25 | -21.5% | 37.3% | ||
| Q2 25 | -24.9% | 35.7% | ||
| Q1 25 | -24.4% | 34.0% | ||
| Q4 24 | -39.3% | 32.3% | ||
| Q3 24 | -20.7% | 31.9% | ||
| Q2 24 | -22.3% | 34.0% |
| Q1 26 | -40.9% | 31.5% | ||
| Q4 25 | -14.1% | 26.7% | ||
| Q3 25 | -22.3% | 28.3% | ||
| Q2 25 | -25.3% | 27.0% | ||
| Q1 25 | -22.1% | 25.7% | ||
| Q4 24 | -40.9% | 24.6% | ||
| Q3 24 | -19.7% | 24.1% | ||
| Q2 24 | -22.2% | 26.0% |
| Q1 26 | — | $1.64 | ||
| Q4 25 | $-0.22 | $1.33 | ||
| Q3 25 | $-0.33 | $1.37 | ||
| Q2 25 | $-0.36 | $1.27 | ||
| Q1 25 | $-0.31 | $1.12 | ||
| Q4 24 | $-0.61 | $1.08 | ||
| Q3 24 | $-0.28 | $1.08 | ||
| Q2 24 | $-0.31 | $1.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $432.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $330.7M | $2.7B |
| Total Assets | $787.9M | $22.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $432.0M | — | ||
| Q4 25 | $93.5M | $1.7B | ||
| Q3 25 | $342.1M | — | ||
| Q2 25 | $149.6M | — | ||
| Q1 25 | $127.3M | — | ||
| Q4 24 | $163.8M | $1.2B | ||
| Q3 24 | $185.4M | — | ||
| Q2 24 | $164.8M | — |
| Q1 26 | $330.7M | $2.7B | ||
| Q4 25 | $340.5M | $2.7B | ||
| Q3 25 | $341.3M | $2.8B | ||
| Q2 25 | $349.4M | $2.7B | ||
| Q1 25 | $362.0M | $2.7B | ||
| Q4 24 | $360.2M | $2.6B | ||
| Q3 24 | $360.8M | $2.7B | ||
| Q2 24 | $361.8M | $2.5B |
| Q1 26 | $787.9M | $22.1B | ||
| Q4 25 | $804.3M | $21.3B | ||
| Q3 25 | $1.4B | $20.8B | ||
| Q2 25 | $1.2B | $20.8B | ||
| Q1 25 | $1.2B | $20.5B | ||
| Q4 24 | $1.2B | $20.8B | ||
| Q3 24 | $1.2B | $20.9B | ||
| Q2 24 | $1.2B | $20.7B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
